Grant: Idea to Innovation
McMaster University
$15,000.00
Market Assessment - Strategic assessment of a therapeutic, bioactive contact lens
FY 2020-21
Summary
Diseases of the cornea, which ultimately cause corneal scarring, are the third most common cause of blindness worldwide. Additionally, corneal injuries and ulcerations, which also lead to corneal scars, result in at least an additional 2 million new cases of monocular blindness. Corneal wound healing is a complex process that requires coordination of various processes including cell migration, cell proliferation, re-stratification, as well as matrix deposition and tissue remodeling. This remodeling is known to be mediated by a number of growth factors, including epidermal growth factor (EGF), which are central to the proper management of corneal wounds. In an effort to aid healing, standard contact lenses are used to bandage the corneal surface after injury; these have limited therapeutic benefit. We propose a bandage silicone hydrogel contact lens with tethered EGF that can accelerate the corneal wound healing response and more importantly control the remodelling process and progression of corneal fibrosis, effectively reducing scarring while maintaining the high oxygen permeability needed for ocular health. This technology could be used in the frontline treatment of cornea-related injury, preventing corneal scarring and reducing associated vision loss and the need for corneal transplants, improving patient outcomes. We request funds to complete a Market Assessment to determine the market segments for this product and what barriers may exist to entry, which will allow us to then create a business plan for successful technology transfer and commercialization.
Program
Idea to Innovation
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
560512-2021
Name nom
Sheardown, Heather
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2021
Award amount
15000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Market Assessment - Strategic assessment of a therapeutic, bioactive contact lens
Keyword
NSERC
Application summary
Diseases of the cornea, which ultimately cause corneal scarring, are the third most common cause of blindness worldwide. Additionally, corneal injuries and ulcerations, which also lead to corneal scars, result in at least an additional 2 million new cases of monocular blindness. Corneal wound healing is a complex process that requires coordination of various processes including cell migration, cell proliferation, re-stratification, as well as matrix deposition and tissue remodeling. This remodeling is known to be mediated by a number of growth factors, including epidermal growth factor (EGF), which are central to the proper management of corneal wounds. In an effort to aid healing, standard contact lenses are used to bandage the corneal surface after injury; these have limited therapeutic benefit. We propose a bandage silicone hydrogel contact lens with tethered EGF that can accelerate the corneal wound healing response and more importantly control the remodelling process and progression of corneal fibrosis, effectively reducing scarring while maintaining the high oxygen permeability needed for ocular health. This technology could be used in the frontline treatment of cornea-related injury, preventing corneal scarring and reducing associated vision loss and the need for corneal transplants, improving patient outcomes. We request funds to complete a Market Assessment to determine the market segments for this product and what barriers may exist to entry, which will allow us to then create a business plan for successful technology transfer and commercialization.